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Abstract
Pluripotent stem cells are invaluable resources to study development and disease, holding a great promise for regenerative
medicine. Here we use human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) from patients with
Huntington’s disease (HD-iPSCs) to shed light into the normal function of huntingtin (HTT) and its demise in disease. We
find that HTT binds ATF7IP, a regulator of the histone H3 methyltransferase SETDB1. HTT inhibits the interaction of the
ATF7IP-SETDB1 complex with other heterochromatin regulators and transcriptional repressors, maintaining low levels of
H3K9 trimethylation (H3K9me3) in hESCs. Loss of HTT promotes global increased H3K9me3 levels and enrichment of
H3K9me3 marks at distinct genes, including transcriptional regulators of neuronal differentiation. Although these genes are
normally expressed at low amounts in hESCs, HTT knockdown (KD) reduces their induction during neural differentiation.
Notably, mutant expanded polyglutamine repeats in HTT diminish its interaction with ATF7IP-SETDB1 complex and trigger
H3K9me3 in HD-iPSCs. Conversely, KD of ATF7IP in HD-iPSCs reduces H3K9me3 alterations and ameliorates gene expression
changes in their neural counterparts. Taken together, our results indicate ATF7IP as a potential target to correct aberrant
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Introduction
Huntington’s disease (HD) is an autosomal dominant neu-
rodegenerative disorder caused by mutations in the huntingtin
(HTT) gene (1,2). These mutations expand the CAG triplet repeat
region in exon 1, resulting in an unstable polyglutamine (polyQ)
stretch in the protein. In its wild-type form, HTT contains
6–35 glutamine residues. However, in individuals affected by
HD, it contains greater than 35 polyQ repeats. Although HTT is
ubiquitously expressed (3,4), mutant HTT particularly leads to
neuronal dysfunction and death in many brain regions with the
striatum undergoing the greatest neurodegeneration (5). Exten-
sive data and the dominant inheritance pattern of HD indicate
that gain-of-function of mutant HTT is toxic and triggers neu-
rodegeneration (1).However, growing evidence suggests that loss
of normal HTT function also contributes to HD (3,4). For instance,
down-regulation of wild-type HTT levels induces HD-related
changes such as progressive neurodegeneration and motor
dysfunction or hastens these changes in HD models (6–10).
Moreover, ectopic expression of wild-type HTT improves brain
cell survival and ameliorates the deleterious effects of the
mutant protein (7,11–17).
Remarkably, conditional knockout ofHtt inmice at embryonic
day 14.5 causes progressive neurodegeneration that mimics HD
phenotypes (6). At earlier stages, complete depletion of HTT
results in severe neural developmental defects and embryonic
lethality (18–20), providing a link between normal function of
HTT and development. Mice with reduced levels of HTT to
below 50% bypass the lethality phenotype but display aberrant
brain development, suggesting a role of HTT in neurogenesis
(21). Loss of HTT during embryonic neurogenesis decreases the
pool of cortical progenitors by accelerating their differentiation,
a process that results in altered cell fate decisions (22). In
vitro, neural progenitor cells (NPCs) derived from Htt-/- mouse
embryonic stem cells (mESCs) can be terminally differentiated
into neurons.However, a study demonstrated that their neuronal
differentiation efficiency is altered as they tend to give rise to
more astrocytes compared with wild-type NPCs (23). Another
study finds even earlier phenotypes such as decreased self-
renewal, increased cell death and alterations in the lineage
potential of NPCs derived from Htt-/- mESCs (24). Although HD
patients andmouse models do not exhibit striking developmen-
tal phenotypes as HTT knockout models (3,21,25,26), cumulative
evidence indicates developmental deficits in HD mouse models
and human pathological specimens (27–30). For instance, polyQ-
expanded HTT induces deficits such as impairment in the
maintenance of striatal neural stem cells and their specification
into medium spiny neurons (30). Furthermore, both HD patients
and mouse models present abnormalities in brain morphology
and synaptic plasticity before the onset of apparent clinical
deficits (31–37).WhenmESCs are genetically modified to express
polyQ-expanded HTT, they maintain their ability to generate
NPCs. Upon neuronal induction, these cells exhibit a higher
percentage of neuronal death resulting in reduced number of
neurons remaining at the end of the differentiation process (23).
Likewise, HD-iPSCs from the patients differentiate into NPCs
with indistinguishable efficiency, although these progenitors
manifest abnormalities in cytoskeleton, cell adhesion, ener-
getics and expression of neural developmental factors (38).
Nevertheless, HD-NPCs can be terminally differentiated into
neurons with alterations in calcium homeostasis and electro-
physiology, increased vulnerability to excitotoxic stressors as
well as cumulative risk of death over time (38). Moreover, neural
cultures differentiated from HD-iPSCs containing neurons,
astrocytes and NPCs present HD-related transcriptional changes
consistent with those observed in the HD brain, including
neurodevelopmental transcription factors and genes involved
in axonal guidance, calcium influx or gamma-Aminobutyric
acid (GABA) signaling (e.g. GABA receptors) (39). In fact,
transcriptional dysregulation is a prominent defect observed in
postmortemHD brains and distinct HDmousemodels [reviewed
in (4,40)]. An increasing number of studies provide evidence
of alterations in epigenetic marks such as DNA methylation
and post-translational modifications of histone proteins
(e.g. H3K3me3) that can contribute to aberrant gene expression
in HD patients as well as HD cellular and organismal models
(40–48). In these lines, neural cultures differentiated from HD-
iPSCs exhibit H3K4me3 and H3K27ac epigenetic alterations (39).
Likewise, targeted mutations that expand the CAG stretch in
one HTT allele are sufficient to impair H3K4me3 marks in both
mESCs and their NPC counterparts (49). A direct role of HTT
in these phenotypes is supported by nuclear export (NES) and
nuclear localization signals within the protein, allowing for its
nuclear localization (50). In addition, polyQ-expandedmutations
impair nuclear export of HTT (51).
Thus, HTT-mediated epigenetic alterations could contribute
to transcriptional abnormalities in HD (44). Among these
epigenetic changes, H3K9 trimethylation (H3K9me3) is robustly
increased in HD patients and HD mouse models (52–55). H3K9
hypermethylation is accompanied by up-regulation of its specific
methyltransferase SETDB1 (54). H3K9me3 is associated with
heterochromatin and correlates with transcriptional repres-
sion (56). In human pluripotent stem cells, the levels of
heterochromatin-associated histone modifications such as
H3K9me3 are usually reduced whereas the levels of tran-
scriptional activations marks such as acetylated histones
are generally increased (57,58). These observations raise an
intriguing question: does HTT maintain low H3K9me3 levels
in pluripotent stem cells?
Here we show that HTT interacts with ATF7IP, a chromatin
factor that regulates SETDB1 activity at heterochromatin forma-
tion sites to facilitate trimethylation of H3K9 (59,60). Knockdown
(KD) of HTT alters the nuclear location of ATF7IP and promotes
its interaction with heterochromatin regulators and transcrip-
tional repressors, resulting in higher global H3K9me3. Thus, HTT
maintains the H3K9me3 landscape of human embryonic stem
cells (hESCs). Conversely, loss of HTT results in enrichment of
H3K9me3 marks in multiple genes, including transcriptional
regulators of neuronal differentiation (e.g. ASCL2, GBX1).
Moreover, H3K9me3 repressive marks at the pluripotent
stem cell stage correlate with reduced induction of these
genes during neural differentiation. We find that expanded
polyQ diminishes the interaction of mutant HTT with ATF7IP
and triggers H3K9me3 in HD-iPSCs. Notably, KD of ATF7IP
decreases H3K9me3 levels in HD-iPSCs. Taken together, our
results indicate a direct role of HTT in the regulation of H3K9me3
via its interaction with the ATF7IP-SETDB1 complex, providing
a target to correct H3K9me3 changes induced by polyQ-
expanded HTT.
Results
HTT interacts with the chromatin regulator ATF7IP
We found that hESCs exhibit higher expression of HTT than
their differentiated neuronal counterparts at both protein and
messenger RNA (mRNA) levels (Fig. 1A and B), supporting a
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Table 1. Protein interactors of HTT in H9 hESCs








Protein LFQ values from co-IP experiments using HTT antibody compared to
control co-IP with FLAG antibody (FDR < 0.05 was considered significant).
partners of HTT inhESCs,we performed co-immunoprecipitation
(co-IP) experiments followed by a single shot label-free pro-
teomic approach. We quantified ∼2000 proteins and compared
protein abundance in HTT antibody pulldowns with control
FLAG antibody pulldowns in both hESCs and terminally differ-
entiated neurons (Supplementary Data 1).AlthoughHTTwas the
most enriched protein in both hESCs and neurons (Fig. 1C and D
and Supplementary Data 1), hierarchical clustering revealed a
clear separation in HTT-interacting proteins between these cells
(Supplementary Material, Fig. S1). Consistent with increased
HTT expression in hESCs (Fig. 1A), we obtained higher amounts
of immunoprecipitated HTT in these cells when compared to
neurons (9.96 versus 6.57 log2-fold enrichment, respectively)
(Fig. 1E and Supplementary Data 1). On the contrary, a major
population of proteins specifically interacted with HTT in
neurons, but not in hESCs (Fig. 1E and F and Supplementary
Data 1). Whereas 102 proteins passed the criterions for
significant interaction with HTT in neurons (Fig. 1D), only
seven proteins were significantly detected in hESCs (Fig. 1C and
Table 1). Among them, NUP201 and U2AF2 were exclusively co-
immunoprecipitated in hESCs whereas the other five proteins
were also detected in neurons (Fig. 1F), including HTT itself
and its known interactors F8A1 (61) and VCP (62). In both
hESCs and neurons, we found a novel interaction of HTT with
ATF7IP (Fig. 1C and D). This transcriptional repressor forms a
complex with the H3K9 methyltransferase SETDB1, which can
translocate to DNA-methylated sites inducing H3K9me3 and
concomitant heterochromatin formation (59,60,63–65). Notably,
co-IP experiments followed by western blot indicated that HTT
could form a complex with both ATF7IP and SETDB1 (Fig. 1G).
Thus, our results suggest that HTT interacts with key epigenetic
regulators.
Loss of HTT alters ATF7IP interactions and induces
H3K9me3 in hESCs
The interaction of ATF7IP-SETDB1 with MBD1, a protein that
binds methylated DNA, results in catalytic activation of SETDB1
and H3K9me3 (59,60,63,64). Moreover, ATF7IP stabilizes SETDB1
in the nucleus of human cell lines (65). We found that the KD of
ATF7IP dramatically diminishes nuclear SETDB1 levels as well
as trimethylation of H3K9 in hESCs (Fig. 2A and B), indicating
that ATF7IP also regulates H3K9me3 in these cells. Interestingly,
reduction of H3K9me3 upon loss of ATF7IP did not affect the
expression of pluripotency markers as assessed by quantitative
polymerase chain reaction (qPCR) (Fig. 2C). To further examine
changes induced by loss of ATF7IP in hESCs, we performed tran-
scriptomic analysis (Supplementary Data 2). These experiments
revealed significant changes [fold change (FC)> 2, P-value< 0.05]
in the steady-state levels of 565 transcripts. Among them, 475
transcripts were up-regulated, of which gene ontology biological
processes (GOBPs) term analysis indicated a strong enrichment
for modulators of transcription, nervous system development,
neuronal differentiation, axon guidance and WNT signaling, a
regulatory node of neural differentiation (66) (Supplementary
Material, Fig. S2 and Supplementary Data 2).
Given that HTT interacted with ATF7IP (Fig. 1), we assessed
whether modulation of HTT impairs H3K9me3 in hESCs, which
normally have low H3K9me3 levels when compared to differ-
entiated cells (57,58). Indeed, we observed a dramatic increase
in H3K9me3 levels upon HTT KD (Fig. 2D and E). Since hESCs
can vary in their characteristics, we examined an independent
hESC line and obtained similar results (Supplementary Material,
Fig. S3A and B). With the role of HTT in brain development
(21), we asked whether alterations in H3K9me3 levels of hESCs
are transmitted to their NPC counterparts. For this purpose, we
performed neural induction of HTT KD hESCs. After 10 days
of neural induction, the expression of the early neuroectoder-
mal marker PAX6 (67) as well as other neural markers were
triggered at the same extent in both control and HTT KD cells
(SupplementaryMaterial, Fig. S4A–C). These results indicate that
HTT is not required for hESC commitment into NPCs. To further
assess differences in these NPCs, we performed RNA sequenc-
ing (RNA-seq) experiments. We found changes in the levels of
195 transcripts (FC > 2, P-value < 0.05), of which 35 were up-
regulated whereas 160 were down-regulated (Fig. 2F and Sup-
plementary Data 3). Among these down-regulated transcripts,
GOBP analysis indicated a strong enrichment for factors involved
in signal transduction, cell adhesion and extracellular matrix
organization (Fig. 2G and Supplementary Data 3). In addition,
reduced HTT levels also decreased the expression of modu-
lators of brain development (e.g. the GABA receptor GABRA5),
synapse assembly (e.g. the neurotrophic receptor NTRK3), glu-
tamate signaling pathway (e.g. the glutamate receptors GRIA3,
GRIN3A, GRIK2) and vesicle fusion/exocytosis (e.g. SYT4, SYT7
and SYTL1,whichmediate Ca2+-dependent exocytosis of neuro-
transmitters) (Fig. 2G and Supplementary Data 3). Notably, NPCs
derived from HTT KD hESCs not only exhibited alterations in
gene expression but also maintained high levels of H3K9me3
compared with control NPCs (Fig. 2H and I).
To gain insights into the regulatory mechanisms by which
HTT regulates H3K9me3 levels, we first asked whether loss of
HTT impairs ATF7IP levels. However, we did not find changes
in the transcript and protein levels of this chromatin factor
upon HTT KD (Fig. 3A and B, Supplementary Material, Table
S1 and Supplementary Data 4). Likewise, loss of HTT did not
affect the protein levels of SETDB1 (Fig. 3B and Supplementary
Material, Table S1). Moreover, co-IP experiments did not show a
significant increase in the interaction of ATF7IP with SETDB1
upon HTT KD (Fig. 3C). However, loss of HTT changed the
nuclear distribution of ATF7IP, which markedly concentrated in
specific areas in contrast to the diffused pattern characteristic of
control hESCs (Fig. 3D). In addition, we observed colocalization
of SETDB1 with these ATF7IP nuclear dots upon HTT down-
regulation (Fig. 3D). Prompted by these results, we examined
whether HTT regulates the interactome of ATF7IP. For this
purpose, we performed co-IP experiments with anti-ATF7IP
antibody in HTT KD hESCs followed by quantitative proteomics
(Supplementary Data 5). Remarkably, hierarchical clustering
indicated clear differences in the binding partners of ATF7IP
upon HTT KD (Supplementary Material, Fig. S5). Whereas
the interaction with SETDB1 remained similar, ATF7IP gained
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Figure 1. HTT interacts with the chromatin factor ATF7IP in hESCs and neurons. (A) Western blot analysis of H9 hESCs and their differentiated counterparts with
antibody to HTT. β-actin is the loading control. The images are representative of three independent experiments. (B) Quantitative PCR (qPCR) analysis of HTT mRNA
levels (mean ± s.e.m. of three independent experiments). Statistical comparisons were made by Student’s t-test for unpaired samples. P-value: ∗∗(P < 0.01). (C) Volcano
plot of HTT interactome in H9 hESCs (n = 3). –log (P-value) of a two-tailed t-test is plotted against the log2 ratio of protein label-free quantification (LFQ) values from
co-IP experiments using HTT antibody compared to control co-IP with FLAG antibody. Blue coloured dots beyond the curved lines indicate significance after correction
for multiple testing [false discovery rate (FDR) < 0.05 was considered significant]. (D) Volcano plot of HTT interactome in neurons (n = 4). Red coloured dots beyond
the curved lines demonstrate significance after correction for multiple testing (FDR < 0.05 was considered significant). (E) Scatterplot of protein enrichments in HTT
co-IP from hESCs and neuronal cells. Significant intrinsic interactors in neurons, hESCs as well as common interactors in both cell types are indicated in red, blue and
magenta, respectively (FDR < 0.05 was considered significant). (F) Venn diagram represents the number of specific and common co-immunoprecipitated proteins with
HTT antibody in hESCs and neurons. (G) Co-IP with HTT and control FLAG antibodies in H9 hESCs followed by western blot with HTT, ATF7IP and SETDB1 antibodies.
The images are representative of three independent experiments.
of HTT which were not detected in control hESCs (Fig. 3E and
Supplementary Data 5). Among them, HTT KD triggered the
interaction of ATF7IP with DNMT3B, a DNA methyltransferase
that establishes DNA methylation patterns in hESCs and
development, a process highly coordinated with histone
methylation (68). Moreover, HTT down-regulation induced the
binding of ATF7IP with SMARCC2, a subunit of the SWI/SNF
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Figure 2. Loss of HTT induces trimethylation of H3K9 in hESCs. (A) Immunocytochemistry of H9 hESCs with antibodies to ATF7IP and SETDB1. Hoechst staining was
used as a marker of nuclei. Scale bar represents 10 μm. The images are representative of two independent experiments. (B) Western blot analysis of H9 hESCs upon
ATF7IP KD with antibodies to ATF7IP, H3K9me3, total H3 and β-actin. The images are representative of two independent experiments. (C) qPCR analysis of pluripotency
markers. Graph (relative expression to NT shRNA H9 hESCs) represents the mean ± s.e.m. of three independent experiments. Statistical comparisons were made by
Student’s t-test for unpaired samples. P-value: ∗∗(P < 0.01). (D) Western blot analysis of H9 hESC lysates with antibodies to HTT, H3K9me3 and total H3. The images are
representative of three independent experiments. (E) Immunocytochemistry of H9 hESCs with antibody to H3K9me3. Hoechst staining was used as a marker of nuclei.
Scale bar represents 20 μm. The images are representative of three independent experiments. (F) Heatmap representing differentially expressed transcripts (FC > 2,
P-value < 0.05) in NPCs derived from HTT KD hESCs identified by RNA-seq analysis (n = 3 biological replicates). (G) GOBP analysis of down-regulated and up-regulated
transcripts in NPCs derived from HTT KD hESCs. For down-regulated transcripts, 15 of the 30 most enriched GOBPs are shown. Please see Supplementary Data 3 for
the complete list of enriched GOBP terms. Statistical comparisons with a modified Fisher’s exact test (EASE score) below the P-value cutoff of 0.05 were considered
significant. (H) Western blot analysis of NPCs derived from H9 hESCs with antibodies to H3K9me3 and total H3. The images are representative of three independent
experiments. (I) Immunocytochemistry of H9 NPCs with antibody to H3K9me3. Hoechst staining was used as amarker of nuclei. Scale bar represents 20 μm. The images
are representative of three independent experiments.
repression and hESC differentiation (69). Likewise, we observed
a strong interaction with protein polybromo-1, a factor that
stabilizes the SWI/SNF complex, and SMARCAD1, an SWI/SNF
regulator that stimulates heterochromatin formation (70). Upon
HTT KD, ATF7IP also interacted with HP1B3, a heterochromatin-
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maintains heterochromatin integrity (71,72). Other interactions
of ATF7IP detected only upon HTT down-regulation were
the non-histone chromatin-associated protein HMGA1, which
mediates the accessibility of protein complexes to DNA during
development (73), and WDR82, a regulator of H3K4 methylation
(74). Besides these chromatin regulators, ATF7IP also gained
interactions with the transcriptional repressor SLTM (75) as
well as GATAD2A/GATAD2B factors, which are recruited by the
scaffolding MBD2 protein at DNA-methylated sites to promote
gene silencing (76). On the contrary, ATF7IP lost the interaction
with distinct chromatin and transcriptional regulators uponHTT
KD (Fig. 3E and Supplementary Data 5). Among them, we found
the histone chaperone NAP1L4 that transfers histones from the
cytoplasm to the nucleus (77) as well as RUVBL2, a regulatory
component of the histone acetyltransferase TIP60 complex
which promotes transcriptional activation (78). Likewise, HTT
KD impaired the interaction of ATF7IP with USP7, an enzyme
involved in chromatin regulation by promoting the deubiquiti-
nation of core subunits of the polycomb repressive complex 1
(PRC1) such as PCGF2 and BMI1 (79). The PRC1 complex
promotes chromatin compaction/gene suppression and is
required for differentiation of ESCs (80,81). Notably, changes in
the interactome of ATF7IP were not associated to dysregulation
in the expression of these proteins, as we observed in proteomic
analysis of HTT KD hESC lysates (Supplementary Material,
Table S1 and Supplementary Data 4). Taken together, our results
indicate that HTT inhibits the binding of the ATF7IP-SETDB1
complex with transcriptional repressors and heterochromatin
regulators, correlating with reduced formation of H3K9me3.
H3K9me3 marks in hESCs upon HTT KD impair
induction of distinct neural genes
Loss of HTT did not impair the levels of pluripotency markers in
hESCs (Fig. 4A and B). Moreover, we found no differences in the
markers of the distinct germ layers (Fig. 4C). To further assess
changes induced by loss of HTT, we analyzed the proteome of
hESCs. Besides HTT, other 14 (9 up-regulated, 5 down-regulated)
proteinswere significantly changed in both independentHTTKD
hESC lines (Supplementary Material, Table S2 and Supplemen-
tary Data 4). Among them, we found an increase in the levels of
laminin subunits (i.e. LAMA1,LAMB1 and LAMC1) andnidogen-1,
a protein tightly associated to laminin (Supplementary Material,
Table S2 and Supplementary Data 4). Moreover, both HTT KD
hESC lines exhibit a significant increase in SUV39H1, a H3K9
methyltransferase (82,83) that can form multimeric complexes
with other H3K9 methylases such as SETDB1 (84) and, therefore,
could contribute to the aberrant H3K9me3 levels observed in
HTT KD hESCs.
Althoughquantitative proteomics revealedmoderate changes
induced by loss of HTT in hESCs, it also presents important
limitations for our study. For instance, this approach could
restrict the quantification of transcription factors as well
as low abundant proteins in hESCs which expression is
triggered during differentiation.We hypothesized that H3K9me3
repressive marks could further decrease the expression of
these genes in hESCs or, more importantly, diminish their
induction during differentiation. To test this hypothesis,
we performed chromatin immunoprecipitation-sequencing
(ChIP-seq) assays of hESCs using an antibody to H3K9me3
(Supplementary Data 6). We found a >1.5-FC enrichment
(P-value < 0.05) for H3K9me3 marks in 3244 regions upon HTT
KD in hESCs (Fig. 4D and Supplementary Data 6). Although
most of them were not associated with genes, 68 contained
gene regions distributed in 19 exons, 19 introns, 29 promoters
and 1 transcription termination site (Fig. 4E, Supplementary
Data 6 and 7). GO term analysis of these genes indicated the
strongest enrichment for factors involved in transcriptional
regulation (Supplementary Material, Fig. S6). These regulators
include three zinc finger proteins (ZNF135, ZNF572, ZNF844),
one transcription elongation factor (TCEB3CL) and three
developmental transcription factors (DLX3, ASCL2, GBX1). DLX3
contributes to ectodermdifferentiation (85).ASCL2 is a proneural
factor involved in the determination of neuronal precursors of
the nervous system and its transcription is regulated via histone
modifications during neural differentiation from hESCs (86).
GBX1 is highly expressed in the neuroectoderm and regulates
the positioning of the midbrain–hindbrain boundary organizer
in the early neural plate, affecting forebrain and midbrain
formation (87). Besides these transcription factors, we found
an enrichment for H3K9me3 in genes involved in nervous
system formation, neuronal function, neurotransmission and
synapse genesis/stabilization [i.e. CELSR1, CPEB1 (88), SMC1B,
ADRA2B, MRGPRX3]. Dysfunctions in calcium homeostasis are
one of the major alterations observed in HD neurons (39,89).
Interestingly, we have found H3K9me3 enrichment in genes
involved in calcium metabolism such as OTOP1, ARPP21 [an
inhibitor of calmodulin-dependent enzymes in striatal neurons
(90)] and OPRD1, which regulates neurotransmitter release by
modulating calcium currents (91). Prompted by these findings,
we asked whether H3K9me3 marks induced by HTT KD results
in decreased expression of these genes. In particular,we focused
on the transcription factors DLX3, ASCL2 and GBX1 because of
their important role in development. Notably,we did not observe
significant changes in the expression of these factors at the
hESC stage (Fig. 4F). With the exception of ASCL2 (FC = −1.29),
early NPCs from HTT KD hESCs (10 days of neural induction)
did not exhibit a significant decreased expression of these
transcription factors when compared with control NPCs by
RNA-seq (Supplementary Data 3). However, it is important to
note that the expression of these genes was still marginal at
the early NPC stage, as reflected by their low FPKM (Fragment
Per Kilobase Million) values (Supplementary Data 3). Indeed,
we confirmed by quantitative PCRthat the expression of ASCL2
and GBX1 was not induced in control NPCs at this early stage
when compared with hESCs (Supplementary Material, Fig. S7).
For this reason, we further differentiated them (20 days on
neural induction treatment) to obtain NPCs with the capacity
to generate terminally differentiated neurons. At this stage,
control NPCs exhibited induced expression of ASCL2, GBX1
and DLX3 when compared to hESCs (Fig. 4G). Thus, we asked
whether H3K9me3 marks in these genes at the hESC stage
impair their induction. Indeed, loss of HTT in hESCs diminished
their ability to induce the expression of ASCL2, GBX1 and DLX3
during differentiation (Fig. 4G). In addition, we confirmed that
HTT KD in hESCs also resulted in decreased expression of other
H3K9me3-enriched genes after 20 days of neural induction
(i.e. SMC1B, ADGRB1) (Supplementary Material, Fig. S8). On the
contrary, we could not detect H3K9me3 enrichment in these
genes when HTT KD hESCs were differentiated into NPCs for
20 days, as the increased H3K9me3 peaks were essentially
distributed in intergenic regions in these cells (Supplementary
Data 8). Thus, our data indicate that H3K9me3 alterations at
earlier stages affect the induction of specific neural genes
during the differentiation process. We then assessed whether
NPCs (20 days neural induction) derived from HTT KD hESCs
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Figure 3. HTT inhibits the interaction of ATF7IP with heterochromatin factors. (A) qPCR analysis of HTT and ATF7IP levels. Graph (relative expression to NT shRNA
H9 hESCs) represents the mean ± s.e.m. of three independent experiments. Statistical comparisons were made by Student’s t-test for unpaired samples [P-value:
∗∗∗∗(P < 0.0001)]. (B) Western blot analysis of H9 hESCs with antibodies to ATF7IP and SETDB1. β-actin is the loading control. The images are representative of
four independent experiments. (C) Co-ip with ATF7IP and FLAG antibodies in H9 hESCs followed by western blot with antibodies to ATF7IP and SETDB1. The graph
represents the relative percentage values to NT shRNA-hESCs of co-immunoprecipitated SETDB1 corrected for immunoprecipitated ATF7IP using anti-ATF7IP antibody
(mean ± s.e.m. of three independent experiments). Statistical comparisons were made by Student’s t-test for unpaired samples and no significant differences were
found. (D) Immunocytochemistry of H9 hESCs with antibody to SETDB1 and ATF7IP. Hoechst staining was used as amarker of nuclei. Scale bar represents 10 μm. On the
right, a higher magnification of representative cells for the different conditions is presented. The images are representative of three independent experiments. (E) log2
LFQ values from co-IP experiments using anti-ATF7IP antibody in NT shRNA and HTT shRNA #1-hESCs (n = 4). For each protein, the bar represents the mean ± s.e.m.
when the signal was detected in at least three replicates of the same condition. The # indicates that signal was not detected in any of the replicates. Statistical
comparisons were made by Student’s t-test. P-value: ∗(P < 0.05).
Although NPCs could differentiate into MAP2-positive neuronal
cells (Supplementary Material, Fig. S9A), the neurons expressed
dysregulated levels of neuronal genes such as synapsin or
the GABA receptor GABBR2 (Supplementary Material, Fig. S9B).
Moreover, they retained abnormal high expression of the neural
marker PAX6 (Supplementary Material, Fig. 9A–C). Altogether,
these results suggest that loss of HTT dysregulates H3K9me3 in
hESCs, a process that could contribute to altered gene expression
upon neural differentiation and affect neurogenesis.
Mutant polyQ-expanded stretch impairs HTT-ATF7IP
interaction
Since our results indicate that HTT interacts with ATF7IP to reg-
ulate H3K9me3, we asked whether polyQ-expanded mutations
alter this normal function of HTT. To assess this hypothesis,
we examined iPSCs derived from an individual with juvenile
onset HD (92). These HD-iPSCs express one mutant copy of HTT
(Q71) but also one normal copy (Q19) (Fig. 5A) (92,93), allowing for
direct assessment of differences between wild-type and mutant
HTT in their interaction with the ATF7IP-SETDB1 complex. For
this purpose, we performed co-IP experiments using either an
antibody against total HTT or polyQ-expandedHTT (94). After we
confirmed the later antibody only immunoprecipitated mutant
HTT, we performed western blot against ATF7IP and SETDB1
(Fig. 5A). Strikingly, we could not detect ATF7IP and SETDB1
in polyQ-expanded HTT pulldowns. On the contrary, anti-total
HTT antibody co-immunoprecipitated these chromatin regu-
lators in HD-iPSCs (Fig. 5A), indicating that mutations in the
polyQ stretch impair HTT interaction with ATF7IP. With the
increased trimethylation of H3K9 in brain tissues of HD patients
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Figure 4. Altered H3K9me3 marks in hESCs upon HTT KD impairs the induction of distinct neural genes. (A) Western blot analysis of H9 hESC lysates with antibodies
to HTT, OCT4 and SOX2. β-Actin is the loading control. (B) The KD of HTT does not change the mRNA levels of pluripotency markers. Graph [relative expression to
non-targeting (NT) shRNA H9 hESCs] represents the mean ± s.e.m. (n = 9). (C) qPCR analysis of ectodermal (PAX6, NES, FGF5), mesodermal (MSX1) and endodermal
(ALB, GATA4, GATA6) germ layermarkers. Graph (relative expression to NT shRNA hESCs) represents themean± s.e.m. (n= 8). (D) Significant H3K9me3-enriched regions
(>2-fold, P < 0.05) upon HTT KD identified by ChIP-seq experiments. The images are representative of two independent experiments. (E) H3K9me3 ChIP-seq profiles of
DLX3, SMC1B and ADGRB1 generated in NT and HTT shRNA hESCs. (F) qPCR analysis of H9 hESCs. Graph (relative expression to NT shRNA) represents themean ± s.e.m.
of three independent experiments. (G) qPCR analysis after 20 days of neural induction. Graph (relative expression to NT shRNA NPCs) represents the mean ± s.e.m. of
three independent experiments. All the statistical comparisons were made by Student’s t-test for unpaired samples. P-value: ∗(P < 0.05), ∗∗(P < 0.01), ∗∗∗(P < 0.001),
∗∗∗∗(P < 0.0001).
exhibit impaired H3K9me3 levels. Similar to HTT KD hESCs,
Q71 HD-iPSCs had increased H3K9me3 levels when compared
to control iPSCs (Fig. 5B). Likewise, an independent HD-iPSC line
expressing normal HTT (Q18) and a distinct mutant HTT allele
(Q180) (38,92,93) also exhibited higher H3K9me3 (Fig. 5B). When
HD-iPSCs were differentiated into NPCs (20 days of neural dif-
ferentiation), these cells exhibited dramatic alterations in gene
expression compared with control NPCs (Supplementary Data
9). RNA-seq experiments revealed that 2171 transcripts were
up-regulated in HD-NPCs (Q180) (FC > 2, P-value < 0.05), of
which GOBP analysis indicated the strongest enrichment for
genes involved in transcriptional regulation, organismal devel-
opment and cell adhesion (Fig. 5C and Supplementary Data 9).
On the contrary, the steady-state levels of 2143 transcripts were
down-regulated with GOBP enrichment for factors involved in
signal transduction, cell adhesion and extracellular matrix orga-
nization (Fig. 5C and Supplementary Data 9). Moreover, these
down-regulated genes were also enriched for modulators of
organismal development, cell differentiation, brain development
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(e.g. NTRK1), chemical synaptic transmission and regulation of
Ca2+ cytosolic levels (e.g.G-protein coupled receptors GNA15 and
GPR6) (Fig. 5C and Supplementary Data 9). Among these down-
regulated transcripts, we found ASCL2 and DLX3, but not GBX1
or SMC1B (Supplementary Data 9).
Prompted by these findings, we examined whether loss of
ATF7IP diminishes trimethylation of H3K9 in NPCs derived from
HD-iPSCs. Indeed, we found that ATF7IP KD after differentiation
is sufficient to reduceH3K9me3 levels in HD-NPCs (Fig. 6A). Since
differentiation of HD-iPSCs generates NPCs that already present
HD-related changes (38,39), one step further was to reduce
H3K9me3 levels at the pluripotent state. Notably, KD of ATF7IP
diminished H3K9me3 levels in HD-iPSCs (Figs 6B–D) without
affecting the expression of distinct pluripotency markers
(Supplementary Material, Fig. S10). To further characterize
the effects of ATF7IP KD in HD-iPSCs, we examined mutant
HTT aggregates. Under normal conditions, HD-iPSCs suppress
mutant HTT aggregation through their intrinsic proteasome and
protein folding activities, which are enhanced in these cells
(2,38,93,95–97). However, dysregulation of either the ubiquitin
proteasome system or the chaperone network triggers mutant
HTTaggregation in these cells (2,38,93,95–97).On the contrary,we
did not detect mutant HTT aggregates in HD-iPSCs upon ATF7IP
KD, indicating that this treatment does not have deleterious
effects on HTT aggregation (Supplementary Material, Fig. S11).
Prompted by these results, we asked whether KD of ATF7IP at
the pluripotent stage can correct alterations in gene expression
of NPCs differentiated from HD-iPSCs. For this purpose, we
induced neural differentiation (20 days) of ATF7IP KD HD-iPSCs
and analyzed their transcriptome (Supplementary Data 10).
Among the 2171 transcripts up-regulated in HD-NPCs com-
pared with control NPCs, ATF7IP KD significantly (FC > 2,
P-value < 0.05) decreased the levels of 1263 transcripts in
HD-NPCs whereas 34 transcripts were further up-regulated
(Fig. 6E and Supplementary Data 11). Regarding the 2143
transcripts down-regulated in HD-NPCs compared with control
NPCs, ATF7IP KD significantly rescued the expression of
852 transcripts (e.g. DLX3) whereas only 44 transcripts were
further down-regulated (Fig. 6E and Supplementary Data 11).
Notably, we found that ATF7IP KD rescues the expression of
PPP1R1B (also known as DARPP32) (Supplementary Data 11),
which is highly expressed in striatal neurons and markedly
decreased in the brains of HD patients and mouse models
(43). Altogether, our data suggest that modulation of ATF7IP
in HD-iPSCs can ameliorate alterations in H3K9me3 levels
and reduce gene expression changes in their NPC counter-
parts.
Discussion
The ubiquitous subcellular localization of HTT does not
facilitate the definition of its function. Multiple roles have been
described for wild-type HTT. For instance, HTT is involved in
vesicular transport (98–100), mitotic spindle orientation (22) and
regulation of selective autophagy (101). Besides a gain of function
in HTT, loss of normal function could also contribute to HD (3,4).
Thus, defining its normal function is of central importance.
In these lines, HTT modulates gene expression by binding
numerous transcription factors and regulators such as the
cAMP-response element-binding protein, specificity-protein 1,
neuroD1,p53 or the nuclear factor-κB (NF-κB) (4). Loss of function
of HTT could explain the transcriptional dysregulation observed
in postmortem HD brains and mouse models (4,40). Moreover,
epigenetic marks including DNA methylation and histone
modifications are impaired in both HD patients and organismal
models (44). Studies in mESCs supported a role of HTT in
the regulation of their epigenetic landscape. In these cells,
HTT facilitates trimethylation of H3K27 by the chromatin
regulator polycomb repressive complex 2 (PRC2), a mechanism
further induced by a gain of function of the mutant HTT (102).
Moreover, expression of polyQ-expanded HTT in mESCs impairs
H3K4me3 deposition at active loci (49). Neural cultures from HD
patient-iPSCs also have alterations in H3K4me3 and H3K27ac,
affecting the expression of distinct neurodevelopmental factors
(39).
Here we find that HTT interacts with the ATF7IP-SETDB1
complex, a key regulator of H3K9me3. Our results indicate that
the high expression of HTT in hESCs blocks the interaction
of ATF7IP-SETDB1 with specific regulators of heterochromatin
and transcriptional repression, a central process to induce
H3K9me3 at heterochromatin formation sites (59,60,63,64).
Conversely, loss of HTT facilitates trimethylation of H3K9
in hESCs, which is normally reduced in these cells when
compared to their differentiated counterparts (57,58). As
such, HTT is required to maintain low levels of H3K9me3
in hESCs. Although H3K9me3 deposition in genes encoding
for neurodevelopmental factors does not affect their low
expression in hESCs, it correlates with their down-regulated
induction during neural differentiation. Thus, HTT allows
for hESC differentiation into neural progenitors with normal
expression of distinct neurodevelopmental factors, including
ASCL2 and GBX1. It will be fascinating to examine whether
the effects of HTT on ATF7IP also modulate H3K4me3 and
H3K27me3 alterations induced by loss of HTT in ESCs. In these
lines, we found that HTT KD induces ATF7IP interaction with
WDR82, a regulator of H3K4me3. Whereas HTT modulates
H3K27me3 levels via PRC2 in ESCs, we did not observe ATF7IP
interaction with the main components of this complex (i.e.
SUZ12, EED, EZH1/2 and histone-binding protein RBBP4) in
control or HTT KD hESCs (Supplementary Data 5). Thus, HTT
may regulate the epigenetic landscape of pluripotent cells via
distinct mechanisms. Although PRC2 is required for the initial
targeting via H3K27me3 of genomic regions to be silenced, the
PRC1 complex stabilizes this silencing promoting chromatin
compaction and gene suppression (103). Notably, we found that
HTT impairs the binding of ATF7IP to USP7, a deubiquitinating
enzyme which interacts with distinct subunits of the PRC1
complex modulating transcriptional repression (79). However,
we did not detect interaction of ATF7IP with core subunits or the
PRC1 complex.
Transcriptional dysregulation contributes to HD pathogene-
sis (40,43,44). Multiple studies in vitro and in vivo support a direct
link of epigenetic alterations in the gene expression changes
associated to HD (40–48). For instance, H3K4me3 dysregulation
alters the expression of genes involved in neuronal function
(42,48). H3K27acmarks are down-regulated inmouse HDmodels
and correlate with down-regulated expression of modulators
of neuronal plasticity and transmission (41). Remarkably,
inhibitors of histone deacetylase can ameliorate HD-related
changes (43). Thus, identifying mechanisms underlying epi-
genetic alterations in HD and their link with transcriptional
dysregulation is of central interest. Although H3K9me3 levels
are up-regulated in the brain of HD patients and mouse
models (52–55), relatively little is known about the link between
these modifications, transcriptional dysregulation and HD
pathogenesis. Notably, polyQ-expanded HTT lacks the ability
to interact with the ATF7IP-SETDB1 complex, a process that
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Figure 5. Mutations in HTT reduce its interaction with ATF7IP and induce H3K9me3. (A) Co-ip with anti-polyQ-expanded HTT and anti-total HTT antibodies in HD
iPSC line #1 (Q71) followed by western blot with antibodies to polyQ-expanded HTT, total HTT, ATF7IP and SETDB1. The images are representative of three independent
experiments. (B) Immunocytochemistry of control iPSCs #1 (Q33), HD-iPSCs #1 (Q71) and HD-iPSCs #1 (Q180) with antibody to H3K9me3. Hoechst staining was used as a
marker of nuclei. Scale bar represents 20 μm. The images are representative of three independent experiments. (C) GOBP analysis of down-regulated and up-regulated
transcripts in NPCs derived fromHD-iPSCs #1 (Q180) after 20 days of neural induction compared with NPCs from control iPSCs #1 (Q33). About 15 of the 30most enriched
GOBPs are shown. Please see Supplementary Data 9 for complete list of enriched GOBP terms. Statistical comparisons with a P-value < 0.05 (modified Fisher’s exact
test) were considered significant.
iPSCs derived from HD patients. When these cells differentiate
into NPCs, they exhibit down-regulated levels of numerous
genes enriched in biological processes linked with nervous
system development and neuronal function, including axon
guidance and chemical synaptic transmission as previously
identified in disease models (43). Although these HD-NPCs
present down-regulated expression of ASCL2 and DLX3, they
do not present decreased levels of all the neurodevelopmental
factors observed in HTT KD cells. It is important to note
that the available HD-iPSC lines, including the ones used
in this study, not only express mutant HTT but also one
normal copy (38,93,104), which could be sufficient to reduce
the impact of diminished mutant HTT interaction with ATF7IP-
SETDB1. Moreover, these results support the findings in HD
patients and disease mouse models, which do not manifest
developmental phenotypes at the same extent than HTT
knockout models (3,21,25,26). Nevertheless, our data indicate
that polyQ-expanded mutations could alter the ability of HTT
to regulate ATF7IP-SETDB1, impairing H3K9me3 levels in iPSCs.
Conversely, loss of ATF7IP in HD-iPSCs reduces trimethylation
of H3K9 and corrects numerous gene expression changes in
HD-NPCs. Among them, we found that ATF7IP KD rescues the
down-regulated expression of DLX3 and PPP1R1B/DARPP32,
which is dysregulated in HD patients and mouse models (43).
Whether diminished interaction of mutant HTT with ATF7IP-
SETDB1 contributes to HD is unknown. Remarkably, a recent
study reported that genetic variations in ATF7IP correlate with
age of onset in HD patients (105). Thus, it will be fascinating
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Figure 6. KD of ATF7IP reduces H3K9me3 levels in HD-iPSCs. (A) KD of ATF7IP in NPCs (20 days of neural induction) decreases H3K9me3 levels as assessed bywestern blot
experiments. The images are representative of two independent experiments. (B) Western blot analysis of HD-iPSC line #2 (Q180) lysates with antibodies to H3K9me3
and total H3. β-actin is the loading control. The images are representative of three independent experiments. (C) Western blot analysis of HD-iPSC line #1 (Q71) lysates
with antibodies to H3K9me3 and total H3. β-Actin is the loading control. Images are representative of two independent experiments. (D) Immunocytochemistry of
control iPSC line #3 (Q21), HD-iPSC line #1 (Q71) and HD-iPSC line #2 (Q180) with antibody to H3K9me3. Hoechst staining was used as a marker of nuclei. Scale bar
represents 20 μm. Images are representative of three independent experiments. (E) Heatmap representing transcripts differentially expressed in NT shRNA HD-NPCs
(Q180) versus NT shRNA control-NPCs (Q33) (P< 0.05, FC> 2). The heatmap also presents the levels of these transcripts in ATF7IP shRNAHD-NPCs (Q180) for comparison.
NPCs were induced during 20 days on neural media (n = 3 biological replicates).
Materials and Methods
hESC/iPSC culture and differentiation
The H9 (WA09) and H1 (WA01) hESC lines were obtained from
the WiCell Research Institute. ND36997 (control iPSC line #1,
Q33), ND42242 (control iPSC line #2, Q21) and ND36999 (HD-iPSC
line #2, Q180) were obtained from NINDS Human Cell and Data
Repository through Coriell Institute. These iPSC lines were gen-
erated and fully characterized for pluripotency in (38). HD-iPSC
(Q71) line #1 was a gift from G.Q. Daley and fully characterized
for pluripotency in (92). Both HD-iPSC (Q71) and HD-iPSC (Q180)
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hESCs and iPSCs were maintained on Geltrex (Thermo Fisher
Scientific, Darmstadt, Germany) using mTeSR1 media (Stem Cell
Technologies, Cologne, Germany). Undifferentiated hESC/iPSC
colonies were passaged using a solution of dispase (2 mg ml-1)
and scraping the colonies with a glass pipette. All the cell lines
used in this study were tested for mycoplasma contamination
at least once every three weeks. No mycoplasma contamination
was detected. Research involving hESC lineswas performedwith
approval of the German Federal competent authority (Robert
Koch Institute).
We induced neural differentiation of hESCs/iPSCs with
STEMdiff Neural Induction Medium (Stem Cell Technologies)
following themonolayer culturemethod as previously described
(106). Undifferentiated cells were rinsed once with Phosphate
Buffered Saline (PBS) and then we added 1 ml of Gentle
Dissociation Reagent (Stem Cell Technologies) for 10 min. After
the incubation period, we gently dislodged hESCs/iPSCs and
add 2 ml of Dulbecco’s Modified Eagle Medium (DMEM)-F12
(Thermo Fisher Scientific) + 10 μM ROCK inhibitor (Abcam,
Cambridge, UK). Then, we centrifuged cells at 300 g for 10 min.
hESCs/iPSCs were resuspended on STEMdiff Neural Induction
Medium + 10 μM ROCK inhibitor and plated on polyornithine
(15 μgml−1)/laminin (10 μgml−1)-coated plates at a density of
200 000 cells cm−2.
For pan-neuronal differentiation, NPCs derived from hESCs
were cultured on neural induction media for at least 20 days.
Then,NPCswere dissociatedwith Accutase (StemCell Technolo-
gies) and transferred to polyornithine/laminin-coated plates in
neuronal differentiation medium consisting of DMEM/F12, B27,
N2 (Thermo Fisher Scientific), 1 μg ml−1 laminin (Thermo Fisher
Scientific), 20 ng ml−1 GDNF (Peprotech, Hamburg, Germany),
20 ng ml−1 BDNF (Peprotech), 200 nM ascorbic acid (Sigma,
Hamburg, Germany) and 1 mm dibutyryl-cyclic AMP (Sigma)
(107). Cells were differentiated for 1 month, with weekly feeding
of neuronal differentiation medium.
Lentiviral infection of hESCs/iPSCs
Lentivirus (LV)-non-targeting short hairpin (shRNA) con-
trol, LV-HTT shRNA #1 (TRCN0000322961), LV-HTT shRNA #2
(TRCN0000019869), LV-ATF7IP shRNA #1 (TRCN0000020827) and
LV-ATF7IP shRNA #2 (TRCN0000338504) in pLKO.1-puro vector
were obtained from Mission shRNA (Sigma). To obtain shRNA
stable lines (108), hESC/iPSC colonies growing on Geltrex were
incubated with mTesR1 medium containing 10 μM ROCK
inhibitor for 1 h and individualized using Accutase. Fifty
thousand cells were infected with 20 μl of concentrated LV in
the presence of 10 μM ROCK inhibitor for 1 h. Cell suspension
was centrifuged to remove virus, passed through a mesh of
40 μM to obtain individual cells, and plated back on a feeder
layer of mitotically inactive mouse embryonic fibroblasts (MEFs)
in DMEM/F12, 20% knockout serum replacement (Thermo Fisher
Scientific), 0.1 mm non-essential amino acids, 1mm L-glutamine,
β-mercaptoethanol and 10 ng ml−1 bFGF (Joint Protein Central,
Incheon, Korea) supplemented with 10 μM ROCK inhibitor. After
several days in culture, small hESC/iPSC colonies arose. Then,
we performed 1 μg ml−1 puromycin selection during 2 days and
colonies were manually passaged onto fresh MEFs to establish
new hESC/iPSC stable lines.
Sample preparation for quantitative proteomics and
analysis
For the comparison between control and HTT KD H9 hESCs,
we performed label-free quantitative (LFQ) proteomics (Sup-
plementary Data 4). Cells were collected in urea buffer
[8 M urea, 50 mm ammonium bicarbonate and 1× complete
protease inhibitor mix with EDTA (Roche, Berlin, Germany)],
homogenized with a syringe and cleared using centrifugation
(16 000 g, 20 min). Supernatants were reduced (1 mm DTT,
30 min); alkylated [5 mm iodoacetamide (IAA), 45 min] and
digested with trypsin at a 1:100 w/w ratio after diluting
urea concentration to 2 M. The day after, samples were
cleared (16 000 g, 20 min) and supernatant was acidified.
Peptides were cleaned up using stage tip extraction (109). The
liquid chromatography tandem mass spectrometry equipment
consisted out of an EASY nLC 1000 coupled to the quadrupole-
based QExactive instrument (Thermo Fisher Scientific) via a
nano-spray electro-ionization source. Peptides were separated
on an in-house packed 50 cm column (1.9 μm C18 beads,
Dr Maisch) using a binary buffer system: (A) 0.1% formic acid
and (B) 0.1% formic acid in acetonitrile (ACN). The content of
buffer B was raised from 7 to 23% within 120 min and then
increased to 45% within 10 min. Then, buffer B fraction was
raised to 80% within 5 min and held for further 5 min after
which it was decreased to 5% within 2 min and held there for
further 3 min before the next sample was loaded on the column.
Eluting peptides were ionized by an applied voltage of 2.2 kV.
The capillary temperature was 275◦C and the S-lens RF level
was set to 60. MS1 spectra were acquired using a resolution of
70 000 (at 200 m/z), an automatic gain control (AGC) target of 3e6
and a maximum injection time of 20 ms in a scan range of 300–
1750 Th. In a data dependent mode, the 10 most intense peaks
were selected for isolation and fragmentation in the HCD cell
using a normalized collision energy of 25 at an isolation window
of 2.1 Th. Dynamic exclusion was enabled and set to 20 s. We
used the following MS/MS scan properties: 17.500 resolution at
200 m/z, an AGC target of 5e5 and a maximum injection time
of 60 ms. All label-free proteomics data sets were analyzed
with the MaxQuant software (release 1.5.3.8). We employed the
LFQ mode (110) and used MaxQuant default settings for protein
identification and LFQ quantification. All downstream analyses
were carried out on LFQ values with Perseus (v. 1.5.2.4) (111).
Protein immunoprecipitation for interactome analysis
Cells were lysed in modified Radioimmunoprecipitation assay
(RIPA) buffer [50 mm Tris–HCl (pH 7.4), 150 mm NaCl, 1%
IgPal, 0.25% sodium deoxycholate, 1 mm EDTA, 1 mm PMSF]
supplemented with protease inhibitor (Roche). Lysates were
centrifuged at 10 000 g for 10 min at 4◦C. Then, the supernatant
was collected and incubated with total HTT antibody (Cell
Signaling, #5656, 1:50), polyQ-expanded HTT antibody (DSHB,
MW1, 1:50) or ATF7IP antibody (Proteintech, Manchester, UK,
14699-1-AP, 1:50) for 30min and subsequently with 100 μl Protein
A beads (Miltenyi, Bergisch Gladbach, Germany) for 1 h on the
overhead shaker at 4◦C.As a control, the same amount of protein
was incubated with anti-FLAG antibody (SIGMA, F7425, 1:100) in
parallel. After this incubation, supernatants were subjected to
magnetic column purification. Three washes were performed
using wash buffer 1 [containing 50 mm Tris–HCl (pH 7.4), 150 mm
NaCl, 5% glycerol and 0.05% IgPal]. Next, columns were washed
five times with wash buffer 2 [containing 50 mm Tris–HCl (pH
7.4), 150 mm NaCl]. Then, columns were subjected to in-column
tryptic digestion containing 7.5 mm ammonium bicarbonate,
2 M urea, 1 mm DTT and 5 ng ml-1 trypsin. Digested peptides
were eluted using two times 50 μl of elution buffer 1 containing
2 M urea, 7.5 mm Ambic and 5 m IAA. Digests were incubated
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Samples were stage tipped the next day for LFQ proteomics and
analyzed with MaxQuant software. The downstream analyses
were carried out on LFQ values with Perseus (v. 1.5.2.4). For co-IP
assays followed by western blot, the pellet was incubated after
the washing steps with 2× Laemmli Buffer, boiled for 5 min
and centrifuged 5min at maximum speed. The supernatant was
taken and loaded onto a sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) gel for western blot analysis.
ChIP-sequencing
Cells were crosslinked with 1% formaldehyde for 10min at room
temperature. Crosslinked cells were quenched with 0, 125 M
glycine for 10 min at room temperature and then scraped and
transferred to a 15 ml conical tube on ice. ChIP experiments
from NPCs were performed as described in (112). Regarding
H9 hESCs, cells were centrifuged for 5 min at 4◦C followed by
two washing steps with 5 ml PBS 1×/PMSF 1 mm as previously
described (113). H9 hESCs were then resuspended sequentially
in three different lysis buffers [lysis buffer 1: 50 mm Hepes,
140 mm NaCL, 1 mm EDTA, 10% glycerol, 0.5% NP-40, 0.25%
TX-100 and protease inhibitor (Roche); lysis buffer 2: 10 mm
Tris, 200 mm NaCL, 1 mm EDTA, 0.5 mm EGTA; lysis buffer 3:
10 mm Tris, 100 mm NaCL, 1 mM EDTA, 0.5 mm EGTA, 0.1%
Na-Deoxycholate, 0.5% N-Lauroylsarcosine]. Chromatin was
then sonicated for 20 cycles (30 s on, 45 s off) using Bioruptor
(Diagenode, Seraing, Belgium).After sonication, thematerial was
centrifuged at 16 000 g during 3min at 4◦C,with the supernatant
representing the sonicated chromatin. About 75 μl was not
subject to immunoprecipitation, thus representing total input
control for the ChIP reactions. A total of 750 μl was incubated
with 10 μg of anti-H3K9me3 antibody (Abcam, #8898, reported
suitable for ChIP) overnight at 4◦C.Onday 2,magnetic Dynabeads
G (Thermo Fisher Scientific) at 10× volume of H3K9me3 antibody
were aliquoted into a new microtube. Magnetic beads were
washed five times with cold RIPA wash buffer (50 mm Hepes,
500 mm LiCl, 1 mm EDTA, 1% NP-40, 0.7% Na-Deoxycholate).
Next, beads were washed once with 1 ml TE + 50 mm
NaCl on ice and sample was centrifuged at 950 g for 3 min at
4◦C. After removing all liquid from beads, elution buffer (50 mm
Tris, 10 mm EDTA, 1% SDS) was added for 15 min at 65◦C. Finally,
beads were centrifuged for 1 min at 1600 g and placed on a
magnetholder to settle and the supernatant was transferred
into a new tube. To reverse crosslinking, 3× volume of the elution
buffer was added to the input and left to incubate together with
the ChIP sample at 65◦C overnight. On day 3, 1× volume of TE
buffer and 0.2 mg ml-1 RNase were added and incubated for
1 h at 37◦C. Afterwards, 0.2 mg ml-1 Proteinase K was added
and incubated for 2 h at 55◦C to digest proteins. Next, DNA
was phenol-chloroform extracted at room temperature with
1× volume of 25:24:1 phenol-chloroform-isoamyl alcohol and
centrifuged for 5 min to separate layers, followed by the addition
of 1× volume chloroform. The DNA was then transferred to a
new tube for precipitationwith 1/10 of NaOAc 3M,1 μl 20mgml-1
glycogen, 2× volume of ice cold ethanol during 30 min at −80◦C.
After a centrifugation during 30 min at 4◦C, the supernatant was
removed and we added 0.5 ml ice cold 70% ethanol followed by
5 min centrifugation. After removing the ethanol, the pellet was
air-dried at room temperature and resuspended in 40 μl dH2O.
ChIP-seq libraries from ChIP and input DNAs were prepared
as described before (114). Libraries fromH9 hESCs andNPCswere
sequenced with a 2 × 75 bp read length on Illumina HiSeq4000
and HiSeq3000, respectively. For ChIP-seq, two biological
replicates from independent experiments were analysed by
using QuickNGS (Next-Generation Sequencing) pipeline (115).
Quality check of sequencing data was performed with FastQC
version 0.10.1 (Babraham Bioinformatics, Cambridge, UK). ChIP-
seq sequencing reads were mapped with Burrows–Wheeler
Aligner (116) to the Homo sapiens genome (Ensembl database
version 87). For peak calling, the resulting Binary Alignment/Map
files were analsed with MACS2 version 2.0.10 (117). The results
comprise lists of significant peaks compared with the respective
inputDNA controls.QuickNGSpipeline identifies all geneswhich
are 2000 bp up- or downstream from the MACS2 peaks. To
identify differential read-enriched peak regions from ChIP-seq
data between different conditions, we used bdgdiff module of
MACS2. Data were uploaded into MySQL database. QuickNGS
also provides password-protected track hubs for the UCSC
Genome Browser with direct hyperlinks for visualization. For
the analysis of the distribution of H3K9me3 peaks, regions
were annotated using HOMER tool (118) and default parameters
except ENSMEBL GTF file version release 81.
RNA seq
Total RNA was extracted using RNAbee (Tel-Test Inc.,
Friendswood, TX, USA). Libraries were prepared using the
TruSeq Stranded mRNA Library Prep Kit. Library preparation
started with 1 μg total RNA. After selection (using poly-T oligo-
attached magnetic beads), mRNA was purified and fragmented
using divalent cations under elevated temperature. The RNA
fragments underwent reverse transcription using random
primers followed by second strand complementary DNA (cDNA)
synthesis with DNA Polymerase I and RNase H. After end repair
and A-tailing, indexing adapters were ligated. The products
were then purified and amplified (20 μl template, 14 PCR cycles)
to create the final cDNA libraries. After library validation and
quantification (Agilent 2100 Bioanalyzer), equimolar amounts of
library were pooled. The pool was quantified by using the Peqlab
KAPA Library Quantification Kit and the Applied Biosystems
7900HT Sequence Detection System. The pool was sequenced on
an Illumina HiSeq 4000 sequencer with a paired-end (2 × 75 bp)
protocol.
RNA-seq data were analysed using a QuickNGS pipeline
(115). Basic read quality check was performed using FastQC
and read statistics were obtained with SAMtools. The basic data
processing consists of a splicing-aware alignment using Tophat2
(119) followed by reference-guided transcriptome reassembly
with Cufflinks2 (120,121). Read count means, FC and P-values
were calculated with DEseq2 (122) and gene expression for the
individual samples was calculated with Cufflinks2 (120,121)
as FPKMs, using in both cases genomic annotation from the
Ensembl database version 87.
Western blot
Cells were scraped from tissue culture plates and lysed in
protein cell lysis buffer [10 mm Tris–HCl, pH 7.4, 150 mm
NaCl, 10 mm EDTA, 50 mm NaF, 1% Triton X-100, 0.1% SDS
supplemented with 20 μg ml-1 Aprotinin, 2 mm sodium
orthovanadate, 1 mm phenylmethylsulphonyl fluoride and
protease inhibitor (Roche)] by incubating samples for 10 min
on ice and homogenization through 27G syringe needle.
Then, cell lysates were centrifuged at 10 000 g for 10 min
at 4◦C and the supernatant was collected. Protein concen-
trations were determined with a standard BCA protein assay
(Thermo Fisher Scientific). Total protein was separated by
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Darmstadt, Germany) and subjected to immunoblotting.
Western blot analysis was performed with anti-total HTT (Cell
Signaling, #5656, 1:1,000), anti-polyQ-expanded HTT (DSHB,
MW1, 1:500), anti-ATF7IP (Proteintech, 14699-1-AP, 1:500), anti-
SETDB1 (Abcam, #107225, 1:500), anti-H3K9me3 (Abcam, #8898,
1:1,000), anti-H3 (Cell Signaling, #2650, 1:10,000), anti-OCT4 (Stem
Cell Technologies, #60093, 1:500), anti-SOX2 (Abcam, #97959,
1:1,000), anti-PAX6 (Stem Cell Technologies, #60094, 1:200) and
anti-ß-actin (Abcam, #8226, 1:1,000).
Immunocytochemistry
Cells were fixed with paraformaldehyde (4% in PBS) for 30 min,
followed by permeabilization (0.2% Triton X-100 in PBS for
10 min) and blocking (3% BSA in 0.2% Triton X-100 in PBS for
10 min). Cells were incubated in primary antibody for 2 h at
room temperature [Mouse anti-SETDB1 (Abcam, #107225, 1:200),
Rabbit anti-ATF7IP (Proteintech, #14699-1-AP, 1:500), Rabbit
anti-H3K9me3 (Abcam, #8898, 1:500), Mouse anti-OCT4 (Stem
Cell Technologies, #60093, 1:200), Rabbit anti-PAX6 (Stem Cell
Technologies, #60094, 1:300), Mouse anti-MAP2 (Sigma, #1406,
1:200), Mouse anti-polyQ (Millipore, MAB1574, 1:50)]. Then,
cells were washed with 0.2% Triton-X/PBS and incubated with
secondary antibody [Alexa Fluor 488 goat anti-mouse (Thermo
Fisher Scientific, A-11029, 1:500); Alexa Fluor 568 goat anti-rabbit
(Thermo Fisher Scientific, A-11011, 1:500) and 2 μg ml-1 Hoechst
33342 (Life Technologies, #1656104)] for 1 h at room temperature.
About 0.2% Triton-X/PBS and distilled water wash were followed
before the cover slips were mounted.
RNA isolation and real-time qPCR
Total RNA was extracted using RNAbee (Tel-Test Inc.). cDNA
was generated using qScript Flex cDNA synthesis kit (Quantabio,
Beverly, MA, USA). SybrGreen real-time qPCR experiments were
performed with a 1:20 dilution of cDNA using a CFC384 Real-
Time System (Bio-Rad) following the manufacturer’s instruc-
tions. Data were analysed with the comparative 2Ct method
using the geometric mean of ACTB and GAPDH as housekeeping
genes. See Supplementary Table S3 for details about the primers
used for this assay.
Statistical analysis
Statistical comparisons of qPCR data and SETDB1 levels in co-
IP experiments followed by western blot were performed with
Student’s t-test for unpaired samples using GraphPad Prism 6.0.
Significant differences from proteomics data were determined
with Perseus (v. 1.5.2.4) (111) after correction for multiple testing
following the Benjamini–Hochberg procedure, which calculates
false discovery rate (FDR) adjusted P-values.Analysis of enriched
GOBPswere performed using Database for Annotation Visualiza-
tion and Integrated Discovery (123), which provides statistical
comparisons with a modified Fisher’s exact test (EASE score).
We used MACS2 to calculate FC and P-values from ChIP-seq
data, allowing for the identification of significant differential
enriched-peak regions between distinct conditions (117). For
RNA-seq data, FC and P-valueswere calculatedwithDEseq2 (122)
and gene expression for the individual samples was calculated
with Cufflinks2 (120,121) as FPKMs.
Data availability
The accession number for the ChIP-seq and RNA-seq datasets
reported in this paper is GEO: GSE118325.
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